Integrating precision medicine into everyday oncological clinical practice

How to make your molecular tumor boards even more efficient with the help of Molecular Health Guide® (MH Guide)

Bild ist nicht verfügbar

Molecular tumor boards as a key step towards applied precision medicine in hospitals


Precision medicine and personalized medicine are both buzzwords which describe the paradigm shift in medical science today. The efficacy and quality of patient treatment will continue to be optimized thanks to the development of new diagnostic strategies and the use of customized treatment. At the same time, adverse effects will be reduced, which over time will increase cost-effectiveness.

The greatest obstacle along the path towards personalized medicine is not so much the cost, as is often assumed. Instead, it is the full utilization of all of the patient data collected — from the clinical medical history to the highly complex "omics" data sets from tumor tissues and their interdisciplinary assessment in boards.
Bild ist nicht verfügbar

Holistic analyses via "omics" technologies


Establishing molecular tumor boards at hospitals is an important step towards applied precision medicine. Another key development is the diagnostic options which ‘omics’ technologies now offer us when it comes to understanding a disease more thoroughly, integrating these options into tumor boards, and making full use of the relevant technologies.

The complexity of these kinds of holistic approaches inevitably ties up resources and capacities in a way that does not make everyday clinical work any easier for those involved, and it is already multifaceted enough. This means it is all the more important to select technologies which contribute to efficiency and precision.
Arrow
Arrow
PlayPause
Slider

About MH Guide

MH Guide is an end-to-end software solution for hospitals and clinics. It provides assistance in making therapeutic decisions in clinical oncology. The software interprets sequencing data from the DNA of the patient’s tumor and generates interactive medical reports including data on drug efficacy, adverse effects, drug interactions and tolerability so that potentially dangerous options can be ruled out.

MH Guide creates an individual tumor analysis for every patient and offers information about the patient’s genomic data in a clinical context. The outcome enables physicians to make customized therapeutic recommendations and rely upon a molecular-based and precise form of support in clinical findings.

MH Guide highlights

Comprehensive and curated


MH Guide links patient-specific molecular data with internationally published biomedical knowledge (see Fig. 1).
The sources of information MH Guide uses for clinical data interpretation are based on the strictest quality criteria and are reviewed by experts.
These sources are completely transparent and comprehensible, creating a robust foundation for personalized treatment decisions.

Qualitatively compelling


To identify a greater number of relevant genomic anomalies, we conduct our analyses specifically based on the patient’s ethnicity as well as using observed predictive, diagnostic and prognostic biomarkers cited in publications and reviewed databases. A quality report is provided with every MH Guide analysis.

Intelligent


The complex process of clinical interpretation is not only automated at MH Guide, it also permits direct access to the underlying data about biomarkers. Drug information such as registration status and a list of recruiting studies has a direct bearing on everyday clinical work.

Scalable and fast


Avoid bottlenecks in analysis! The key prerequisite in clinically interpreting genome-wide diagnostic data is automated data retrieval, filtering and integrating all of the available relevant knowledge about genetic changes.

Contextualization


An understanding of genetic contexts is a prerequisite for clinically interpreting molecular-genetic data. MH Guide presents these contexts to you in a streamlined and evidence-based manner, and you can integrate your own expertise into the interpretation.

Drug safety


MH Guide features data about drug efficacy and the profile of adverse events based on genomic changes. It offers another source of valuable information by listing drug interactions. This allows MH Guide to provide support in identifying potentially risky treatment strategies and increasing the prospects of greater quality of life during treatment.

Research and interpreting translational data


In addition to clinically validated biomarkers, MH Guide also offers information taken from basic research and labels it accordingly. The research findings can be interpreted and translationally applied, or new hypotheses can be formulated.

Easy to use and always up to date


MH Guide does not require any complicated local installation, and you will not need to deal with operations and maintenance. Molecular Health offers hosted applications as software-as-a-service and handles the data processing and storage for you.
The programs, methods and algorithms needed for MH Guide are constantly being updated, tested and validated. MH Guide is optimized on an ongoing basis with at least two software updates per year and continuous data updates.

Training and support


MH Guide includes professional training and assistance in implementation. By providing contact to our MH Guide-certified physicians, we can support you in generating reports for all of the cases we process.
Arrow
Arrow
Slider

How your hospital can benefit from implementing MH Guide

Creates cost-efficient and highly precise reports for your tumor board and direct routes to efficacious drug-based cancer treatment for your patients

Prevents greater incidence of adverse effects and unnecessary treatments

Saves significant amounts of time for doctors making therapeutic decisions

Offers seamless integration of the process into your diagnostic procedures

Facilitates handling larger numbers of cases per month

Our hospital partners

Ernst Moritz Arndt Universität Greifswald
Universitätsklinikum Düsseldorf
UKE Hamburg
UniversitätsKlinikum Heidelberg
Karolinska Institutet
Hochtaunus Kliniken
Charité